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Besides cytotoxicity, taxanes induce other biological effects, especially in the immune system. Taxanes have demonstrated
immunostimulatory effects against neoplasms, supporting the idea that these agents suppress cancer through several
mechanisms and not solely through inhibiting cell division. The purpose of the present study was to evaluate the effect of
taxanes (paclitaxel and docetaxel) and investigate their ability in alterating important immunological parameters in breast
cancer patients. Thirty women with advanced breast cancer undergoing chemotherapy were randomly assigned into two
groups treated with either single agent Paclitaxel or Docetaxel. Sera from patients before the ﬁrst and after the last treatment
cycle and from normal donors were assayed by ELISA for IL-2, IL-1b, IFN-g, GM-CSF, IL-6, TNF-a, and PGE2 levels. In these
same blood samples, NK and LAK cell activity was tested in the total PBMC population against NK-sensitive K562 tumour
targets, respectively, and autologous mixed lymphocyte reaction was tested by
3H-thymidine proliferation assays. All patients in
both groups responded to therapy. Signiﬁcant differences were observed in the following immune parameters between the
control group of healthy blood donors and the pretreatment values of both taxane groups; IL-2, GM-CSF, IFN-g levels and NK
and LAK cell cytotoxicity were depressed, whereas TNF-a and IL-6 levels were raised in breast cancer patients before
treatment compared to controls. There were no signiﬁcant differences between the two treatment groups regarding any of
the parameters studied. Both drugs led to increases in MLR values, NK and LAK cell cytotoxicity, and IL-6, GM-CSF, IFN-g
levels, and decreases for IL-1, TNF, and PGE2 levels. The percentage of these differences was greater for docetaxel in
comparison to paclitaxel (P50.0001). More speciﬁcally, docetaxel demonstrated a more pronounced effect on enhancing
MLR, NK, LAK activity and IFN-g, IL-2, IL-6, and GM-CSF levels, as well as caused more potent reduction in IL-1 and TNF-a
levels when compared to paclitaxel. The present study indicates that patients responded to treatment of advanced breast
cancer with single-agent paclitaxel or docetaxel leads to an increase in serum IFN-g, IL-2, IL-6, GM-CSF cytokine levels and
enhancement of PBMC NK and LAK cell activity, while they both lead to a decrease of acute phase serum cytokine levels of
IL-1 and TNF-a. Moreover, the effects of docetaxel are in all the above parameters more pronounced than those of paclitaxel.
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Over the last decade, taxanes (namely paclitaxel and docetaxel)
have emerged as effective antitumour agents in a variety of malig-
nancies. Paclitaxel is a semi-synthetic taxane, isolated from the bark
of the Paciﬁc yew tree. Doxetaxel is a semi-synthetic taxane,
derived from the needles of the European yew (Taxus Baccata).
These compounds bind to tubulin, leading to microtubule stabili-
sation, mitotic arrest and, subsequently, cell death. Plasma
clearance of paclitaxel exhibits non-linear kinetics, which results
in a disproportionate change in plasma concentration and area
under the concentration–time curve with dose alterations. In
contrast, docetaxel has a linear disposition over the dose ranges
used clinically, so its concentration changes linearly with changes
in the dosage. The taxanes are metabolised in the liver by the cyto-
chrome P-450 enzymes and are eliminated in the bile. The known
metabolites are either inactive or less potent than their parent
compounds (Aikin, 1999; Miller, 1999; Vaishampayan et al, 1999).
In parallel, taxanes induce other biological effects, especially in
the immune system. Taxanes are immunostimulatory against
neoplasms, supporting the idea that these agents suppress cancer
through several mechanisms and not solely through inhibiting cell
division (Lee et al, 2000a; Tong et al, 2000). Immune function was
affected more signiﬁcantly after docetaxel treatment (Chan and
Yang, 2000). IL-10 serum levels signiﬁcantly decreased in paclitaxel
treated patients (Lee et al, 2000b). Paclitaxel induces IL-8 and this
probably may have a positive role in controlling tumour growth
(Lee et al, 2000a). Paclitaxel restores IL-12 production in the
tumour bearing host and a novel immunotherapeutic component
to the pleiotropic activities of NO is ascribed (Mullins et al,
1998). IL-2, IL-12, and gamma-IFN (IFN-g) levels were not detec-
able, during the administration of taxanes (Mullins et al, 1998; Lee
et al, 2000b). NK cytotoxic activity decreased in docetaxel-treated
patient (Lee et al, 2000b). LAK cell activity was not altered during
the administration of these drugs. Paclitaxel has the capacity to
induce macrophage antitumour cytotoxic activity, and has exhib-
ited no inhibitory effects to concavalin A (ConA)-induced T-cell
proliferation (Lee et al, 2000b).
The objective of the present study was to evaluate the effect of
taxanes (paclitaxel and docetaxel) and investigate their ability in
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patients. The effect of taxanes on the functional properties of
PBMC was correlated with serum cytokine levels as well as with
the clinical course of therapy.
MATERIALS AND METHODS
Patients
Thirty women with advanced breast cancer undergoing chemother-
apy with single agent Paclitaxel or Docetaxel, were evaluable for the
present study and had blood samples collected. Patients were sepa-
rated randomly into two groups; the Paclitaxel Group and the
Docetaxel Group. The clinical characteristics of the patients are
summarised in Table 1. Histologic type and tumour grade were
assessed according to the WHO classiﬁcation (Miller et al, 1981).
Prior to entering the study, patients were clinically evaluated by
physical examination, ECG, chest X-ray and abdominal CT scans,
blood cell count, platelet count, serum biochemical analyses and
urine analyses. Patients were thus assessed routinely every 4 weeks
throughout the duration of the study. The study was approved by
the Scientiﬁc-Ethics committee of our Institution.
Eligibility criteria
All patients completed six chemotherapy courses with taxanes every
21 days, without the use of G-CSF or GM-CSF. Other eligibility
criteria included measurable disease, response to chemotherapy,
performance status (Karnofsky) (PS) equal or 480, life expectancy
43 months, absence of brain metastases unless controlled after
brain irradiation and off steroids, active ischaemic cardiac disease,
normal haematological, renal or hepatic function tests unless the
abnormalities had resulted from direct tumour invasion. A histolo-
gical documentation of measurable metastatic disease was obtained
whenever possible. Patient characteristics are shown in Table 1.
Informed consent was obtained from all patients according to
our Institutional policy.
Randomisation
Patients were randomised to receive Paclitaxel or Docetaxel, and
were allocated into the treatment groups by simple randomisation
(closed envelopes). Age, gender, performance status (Karnofsky)
(PS) and sites of metastases were the same in both arms as indi-
cated in Table 1.
Treatment
Treatment was carried-out in the day clinic. Two groups of
patients were formed according to their therapeutic schedule
(Table 1).
Paclitaxel group Fifteen patients received Paclitaxel was given at
a dose of 200 mg m
72 in 1-h i.v. infusion in normal saline with
premedication (Tsavaris et al, 1997), and recycled every 21 days.
Docetaxel group Fifteen patients received Docetaxel was given at
a dose of 100 mg m
72 in 1-h i.v. infusion of normal saline with
the same premedication with Paclitaxel, and recycled every 21 days.
Premedication was administered in order to avoid any possible
allergic reaction of the patients to taxanes, 4 mg of dimethindene
maleate and 20 mg of dexamethasone were administered i.v. over
30 min i.v. infusion before each taxane; moreover, cetirizine tablets
10 mg and methylprednisolone 16 mg were administered 2 times
daily for 4 days starting 1 day prior to therapy in docetaxel-treated
patients in order to avoid skin rashes and ﬂuid retention.
Treatment was continued until tumour progression. In the event
of grade 4II, myelosuppression, neuropathy, etc (WHO classiﬁca-
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Table 1 Patients’ charateristics; pretreatment and treatment-related
Patients’ characteristics Docetaxel group Paclitaxel group P
Number of patients 15 15 NSS
Pre-menopausal 6 6 NSS
Post-menopausal 9 9 NSS
Estrogen receptors positive 7 7 NSS
Progesteron receptors positive 5 5 NSS
c-erbB-2 positive 7 7 NSS
Adjuvant chemotherapy – CMF 6 6 NSS
Adjuvant chemotherapy – CAF 5 5 NSS
Adjuvant hormonal therapy 4 4 NSS
Median DFI
a (range) 33.5 (5–61) 31.2 (7–57) NSS
Chemotherapy with doxorubicin after relapse 6 5 NSS
Metastases
Lung only 2 3 NSS
Liver only 3 3 NSS
Soft tissue 1 0 NSS
Lung+LN 3 2 NSS
Lung+liver 3 3 NSS
Soft tissue+liver 2 3 NSS
Soft tissue+lung 1 1 NSS
CA 15.3
Normal 6 5 NSS
Normal 530 U
4 normal (median) 54 (48–176) 59 (37–197) NSS
Response
Partial 5 6 NSS
Minor 10 9 NSS
Taxanes
Doses 90 90 NSS
NSS: no statistically signiﬁcant, LN: lymph nodes.
aDFI: Disease free interval.
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did not use G-CSF or GM-CSF except in the case of febrile neutro-
penia. Patients receiving G-CSF were excluded from the study. The
doses for both drugs were kept stable, if no toxicity was encoun-
tered.
Criteria for response
Before each treatment cycle every patient had a complete blood
count, SMA-12, EKG, chest roentgenography, and abdominal CT
scan. Between the treatment cycles CBC’s were performed weekly.
Patients were evaluated for response between the treatment cycles
during the 2-week rest period. Responses were categorised as follows:
(1) Complete response (CR) which was deﬁned as a complete disap-
pearrance of all clinically and radiographically evident disease. (2)
Partial response (PR) was deﬁned as a decrease of more than 50%
in the sum of the products of the largest perpedicular diameters of
the measurable lesions. (3) A 25–50% decrease, without satisfying
the criteria of a PR was deﬁned as minor response (MR).
Toxicity
Toxicity was recorded according to WHO criteria (Miller et al,
1981).
Control group
The control group consisted of healthy volunteers from our hospi-
tal personnel. Twenty healthy individuals who ranged in age from
35–63 years (median 46) were studied. Normal donors were
always studied concurrently with the cancer patients.
Cell puriﬁcation
Peripheral blood from all patients treated with either paclitaxel and
docetaxel was collected in heparinised tubes, initially before the
ﬁrst chemotherapy cycle and subsequently 4 weeks after the sixth
treatment cycle. Blood from age and sex matched hospital staff
volunteers was collected in parallel as for a control. Peripheral
blood mononuclear cells (PBMC) were isolated by centrifugation
over Ficoll-Hypaque density gradient (Pharmacia, Fine Chemicals,
Uppsala, Sweden) as previously described (Baxevanis et al, 1994).
Autologous serum collected from the top of the Ficoll was
aliquoted and stored at 7708C until assayed for cytokine levels.
For each PBMC sample, T lymphocytes (CD3+) and monocytes
(CD14+) were isolated using MACS CD3 Microbeads and the
Monocyte Isolation Kit (Miltenyi, Biotec, Bergisch Gladbach,
Germany) respectively, according to the manufacturer’s instruc-
tions and as described (Baxevanis et al, 2000). Upon puriﬁcation,
cells were washed once and resuspended in RPMI-1640 culture
medium (Gibco, Grand Island, NY, USA), supplemented with
10% foetal calf serum (FCS; Gibco), 2 mML -glutamine (Sigma
Chemical Company, St. Louis, MO, USA), 10 mM HEPES (Gibco)
and 100 mgm l
71 gentamycin (referred to thereafter as complete
medium). The purity of the isolated cell populations was tested
by ﬂow cytometry on a FACScan (Becton Dickinson, Mountain
View, CA, USA), using anti-CD3 and anti-CD14 mAbs conjugated
with PE (Pharmingen, San Diego, CA, USA). In all cases, isolated
CD3+ or CD14+ cells represented 498% of the relative fraction.
Autologous mixed lymphocyte reaction (AMLR)
This was performed as described (Baxevanis et al, 1992). Brieﬂy, T
lymphocytes (10610
4/well) were plated in a 96-well U-bottomed
plate (Greiner, Kirheim u. Teck, Germany) and irradiated (3000
rad) autologous monocytes (5610
4/well) were added to a ﬁnal
volume of 200 ml complete medium/well. Cultures were maintained
for 6 days at 378C, in a CO2 incubator. Eighteen hours prior to
harvesting, cultures were pulsed with 1 mCi/well [
3H] TdR (Amer-
sham, UK), harvested and radioactivity incorporation was
measured in a b-counter (Packard, Cowners Grove, IL, USA). Cell
cultures were set up in triplicates. For each sample AMLR was set
up similarly using as effector cells autologous blasts generated by
incubating T lymphocytes (1610
6 ml) for 3 days in complete
medium supplemented with 10 mgm l
71 PHA in 25 cm
2 ﬂasks.
Cytotoxicity assays
NK cell activity was tested in the total PBMC population against
the NK-sensitive K562 tumour targets. For testing LAK cell activity,
PBMC were cultured for 7 days with 1000 U ml human recombi-
nant IL-2 (Cetus Corp. CA, USA). Lytic activity of these effectors
were tested against the NK-resistant Daudi tumour targets. Cyto-
toxicity assays for assessing NK- or LAK-activity were performed
essentially as recently reported (Baxevanis et al, 1999). Brieﬂy,
effector PBMC, freshly isolated or cultured with IL-2, were plated
in 100 ml aliquots (2610
6 cells ml in complete medium) in 96-well
V-bottomed microtiter plates (Costar, Cambridge MA, USA).
Tumour targets (10
7 cells) were incubated with 100–150 uCi of
sodium [
51Cr] chromate (Amersham) for 60 min at 378C washed
twice to remove excess isotope and a quantity amounting to
5610
3 cells/well was added to the effector cells, to assess an effec-
tor to target (E/T) ratio of 40 to 1. After 18 h incubation at 378C
in a CO2 incubator, 100 ml of supernatant were removed from each
well for isotope counting in a g-counter (Packard, Downers Grove,
IL, USA). Spontaneous and maximum release were estimated by
incubating targets in medium alone and with 1 M of HCl (Merck),
respectively. Spontaneous release did not exceed 15% of the maxi-
mum release. In all cases, cultures were set up in triplicate and%
speciﬁc target cell lysis was calculated as follows:
c:p:m: experimental ÿ c:p:m: spontaneous
c:p:m: maximum ÿ c:p:m: spontaneous
 100
Quantitation of cytokine serum levels
Sera from patients and normal donors were assayed for the deter-
mination of IL-2, IL-1b, IFN-g, GM-CSF, IL-6, TNF-a, and PGE2
using commercially available ELISA kits; for human IL-2, IL-1b,
IL-6, and TNF-a were obtained from R&D Systems (Europe), for
IFN-g and GM-CSF from Endogen (Boston, MA, USA), and for
PGE2 from Advance Magnetics Inc (Cambridge, MA, USA). All
determinations were performed in duplicate.
Statistical analysis
The analysis that follows aims at comparing the effect of treatment
with Paclitaxel to the effects of treatments with Docetaxel on a
number of parameters. For this reason 30 patients participated in
the study (equally distributed between treatments), measurements
were collected for nine parameters; for each parameter, measure-
ments were carried out before treatment and 4 weeks after the
last treatment cycle.
After the administration of six doses of taxanes, data were
collected for all participants in the two time points (before the
administration of treatment and after six doses). The parameters
under study are presented in Table 2. The data analysis was
conducted in three steps. The ﬁrst step evaluated pre-treatment
differences between the three groups of patients. The second step
evaluated the post-treatment differences between groups taking
into account the initial measurements. Pre-treatment differences
between the two groups were tested via one-way analysis of
variance (ANOVA) and differences in treatment effects were tested
via one-way analysis of covariance (ANCOVA).
Variables were compared by means of the w
2 test with Yate’s
correction as appropriate; continuous variables were compared by
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intergroup comparisons. For matched pairs, Student’s t-test or
Wilcoxon’s signed-rank test were applied. Logarithmic transforma-
tion was applied as appropriate in order to correct for distribution
(Dixon and Massey, 1983; Machin and Campbell, 1987). Differ-
ences between mean values of the time-points were assessed
through repeated measurement analysis of variance, using the
statistical package SPSS (Ver. 8.0). The accepted level of signiﬁ-
cance was P50.05.
RESULTS
Patients
A total of 30 evaluable patients were enrolled onto this study, with no
difference in the basic clinical and laboratory parameters (Table 1).
The clinical characteristics (age, menopausal status, Karnofsky index
and site of metastases and extension of the disease) of our patients
were equally balanced between the study groups. In order to ﬁnd
patients who received six cycles of taxane therapy, only those with
at least stable disease were evaluable in the present study. No delays
were noticed in the administration of treatment because of toxicity
or other reasons. Signiﬁcant differences were observed in the follow-
ing immune parameters between the control group of healthy blood
donors and the pretreatment values of both taxane groups; IL-2, GM-
CSF, IFN-g levels and NK and LAK cell cytotoxicity were depressed,
whereas TNF-a and IL-6 levels were raised in breast cancer patients
before treatment compared to controls. Table 2 demonstrates the
P-values calculated for the comparison of the initial measurements
between the two treatment arms, docetaxel and paclitaxel, and the
healthy normal blood donors along with the basic statistical measures
for each subgroup. There were no signiﬁcant differences between
groups with taxanes regarding any of the parameters studied. In
comparison to normal control group, the groups of taxanes presented
statistical signiﬁcant differences in all the examined immunological
parameters, before the initiation of chemotherapy. All the examined
parameters, in taxane treated groups, were found decreased in
comparison to normal control group (P50.007), except PGE2 and
TNF-a (P50.0001) which were found decreased. No difference was
found between the taxane groups (Table 2, Figure 1).
Analysis of pre- and post-treatment differences
Signiﬁcant differences (P50.0001) were observed between post-
treatment values of the examined parameters and the values after
the administration of six courses of each taxane, either paclitaxel
or docetaxel (Table 3). Differences between immunological para-
meter values before the initiation of chemotherapy and after six
courses of chemotherapy were signiﬁcant, both in the Docetaxel-
treated group (P50.0001) and also for Paclitaxel (P50.0001)
(Table 3).
Both drugs led to increases in MLR values, NK and LAK cell
cytotoxicity, and IL-6, GM-CSF, IFN-g levels, and decreases for
IL-1, TNF, and PGE2 levels (Figure 2). The percentage of these
differences was greater for docetaxel in comparison to paclitaxel
(P50.0001). More speciﬁcally, docetaxel demonstrated a more
pronounced effect on enhancing MLR, NK, LAK activity and
IFN-g, IL-2, IL-6, and GM-CSF levels, as well as more potent
reduction in IL-1 and TNF-a levels when compared to paclitaxel
(see also Table 3 and Figure 2).
DISCUSSION
As already mentioned, taxanes are antimitotic drugs with their
major mechanism of action having to do with stabilisation of
microtubules. Increased microtubule stability leads to abnormalities
in the cytoskeleton and the mitotic spindle (Schiff and Horwitz,
1980). While microtubules are well recognised as an integral
component of the cytoskeleton of virtually every human cell, their
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Table 2 Baseline values of immunological parameters before the initiation of chemotherapy for both groups; Pacli-
taxel (PCT) and Docetaxel (DCT), and those of the normal control group
Mean value+s.d.
Immunological Normal
Taxanes
a
PP
parameter (units) controls DCT PCT (DCT vs PCT) (DCT/PCT vs controls)
MLR (c.p.m.610
3)2 5 +5 11.42+1.36 11.68+2.87 0.922 50.0001
NK cells (6ml
71)6 6 +22 24.33+3.24 23.93+2.87 0.927 50.0001
LAK cells (6ml
71)8 8 +42 24.47+3.57 24.33+3.16 0.978 50.0001
IL-1 (pg ml
71) 197+32 121.27+13.1 123.27+12.31 0.912 50.0001
IL-2 (pg ml
71) 275+92 84.33+11.24 82.33+9.67 0.894 50.0001
IL-6 (pg ml
71) 72.15+15 57+7.91 58.53+7.9 0.892 0.006/0.007
PGE (pg ml
71)7 6 +10 157.7+59.76 153.53+50.62 0.932 50.0001
TNF (pg ml
71)5 9 +10 113.27+17.2 101.8+11.7 0.586 50.0001
GM–CSF (pg ml
71) 145+60 95.73+11.1 81.87+11.5 0.4 0.001/0.000
INF-g (pg ml
71) 125+37 57+6.6 61+5.7 0.64 50.0001
aDCT: Docetaxel, PCT: Paclitaxel.
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NCG DCT PCT
Figure 1 Comparison of the percentages of differences, between nor-
mal control group (NCG), Docetaxel (DCT), and Paclitaxel (PCT), before
the administration of taxanes.
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structure support. There is now adequate evidence to support the
fact that microtubules are integrally involved in the production
and release of many peptides, including the pro-inﬂammatory
cytokines interleukin-1b (IL-1b) and tumour necrosis factor-a
(TNF-a). Production of these cytokines, IL-1b and TNF-a, has
been demonstrated to be promoted variably by the reorganisation
of intracellular microtubules (Baldari and Telford, 1989; Ding et
al, 1990; Allen et al, 1991). Paclitaxel, a potent inhibitor of micro-
tubule disassembly, leads to enhanced release of both IL-1b and
TNF-a by human monocytes in vitro in a dose-dependent manner,
at drug concentrations achievable at therapeutic drug administra-
tion in vivo (Bogdan and Ding, 1992; Allen et al, 1993).
However, the aforementioned in vitro effects of paclitaxel on
human monocytes were triggered only when a second stimulus,
such as bacterial endotoxin, was present (Bogdan and Ding,
1992). In contrast, paclitaxel by itself does not enhance transcrip-
tion of IL-1b and TNF-a mRNAS or increase translation of the
pro-IL-1b precursor molecule, or release of IL-1b and TNF-a
(Allen et al, 1993). Similar effects were reported when using alveo-
lar macrophages from normal donors. In the present study, we
observed an absolute reduction of both IL-1 and TNF-a serum
levels before the initiation (baseline) and after six cycles of either
paclitaxel or docetaxel chemotherapy that was statistically signiﬁ-
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Table 3 Immunological parameters, before chemotherapy (D1, T1), and after six cycles
of chemotherapy (D6, T6) with the administered drugs; Docetaxel (D), and Paclitaxel (T)
Immunological
parameters Mean
a s.d. s.e. Mean
a s.d. s.e.
MLR D1 11.42 5.28 1.36 D6 27.81 11.58 2.99
T1 11.68 3.77 0.66 T6 23.41 10.73 3.21
NK D1 24.33 12.54 3.24 D6 73.33 26.96 6.96
T1 23.93 11.13 2.87 T6 45.80 14.45 3.73
LAK D1 24.47 13.82 3.57 D6 53.53 16.64 4.30
T1 24.33 12.25 3.16 T6 40.80 9.39 2.42
IL-2 D1 84.33 43.55 11.24 D6 132.87 51.94 13.41
T1 82.33 37.45 9.67 T6 110.73 37.21 9.61
IL-1 D1 121.27 50.76 13.11 D6 90.40 47.53 12.27
T1 123.27 47.67 12.31 T6 105.67 44.06 11.38
TNF D1 113.27 66.53 17.18 D6 79.33 31.30 13.30
T1 101.80 45.44 11.73 T6 85.53 41.98 10.84
IL-6 D1 57.00 30.62 7.91 D6 106.13 40.53 10.46
T1 58.53 30.51 7.88 T6 81.00 34.06 8.79
PGE2 D1 157.67 59.76 15.43 D6 109.40 50.88 13.14
T1 153.53 50.62 13.07 T6 127.60 43.70 11.28
GM-CSF D1 95.73 43.00 11.10 D6 146.33 50.94 13.15
T1 81.87 44.59 11.51 T6 108.60 43.41 11.21
IFN-g D1 57.00 24.34 6.28 D6 103.07 23.28 6.01
T1 61.00 22.07 5.70 T6 79.73 21.57 5.57
aDifferences in the values of the examined immunological parameters were statistically signiﬁcant
before the initiation of taxane therapy (D1, T1) and after six cycles of taxane monotherapy (D6,
T6) at P50.0001 for all comparisons. D: Docetaxel, T: Paclitaxel.
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Figure 2 Comparison of the percentages of differences, before and after the administration (after six cycles) of both taxanes; Docetaxel and Paclitaxel
(P50.0001).
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monocyte-directed immune reactions, parallels that on IL-1
production. This can be explained by an increase in IL-1 and
TNF-a produced from monocytes recruited in the tumour site
associated with a relative deﬁciency for both cytokines from the
systemic circulation as a result of enhanced local consumption/
degradation. However, this can remain only speculative until
studies in tumour biopsies estimating local IL-1 and TNF-a mRNA
production by in situ hybridisation techniques before and after
taxane chemotherapy are carried-out. Moreover, TNF-a levels were
increased before treatment in our breast cancer patients when
compared to normal controls, and even with their reduction after
treatment with either paclitaxel or docetaxel, never returned to the
levels observed in the healthy control group. Paclitaxel has been
shown to be LPS-mimetic in mice, stimulating signalling pathways
and gene expression indistinguishably from LPS, such as the intra-
cellular signalling pathway of nuclear factor-kappaB (NF-kB)
activation (Lee and Jeon, 2001). It is known that IL-1, TNF-a,
IL-2, IL-6, etc, cytokine gene transcription is positively regulated
by NF-kB.
In contrast, treatment with both taxanes induced a signiﬁcant
increase from pretreatment baseline serum levels of IFN-g, IL-2,
GM-CSF and IL-6. IL-2 and IFN-g represent T-helper-1 (Th1)
cytokines thought to be involved in delayed-type hypersensitivity
(DTH) reactions. GM-CSF is produced by both Th1 and Th2
clones, but is rather more pronounced in Th1-type reactions. In
contrast, IL-6 is an absolutely Th2-derived cytokine. It is therefore
tempting to speculate that taxanes may induce these serum cyto-
kine proﬁles either indirectly by their cytotoxic effect on tumour
cells leading to secondary immune recognition of released
tumour-derived antigens by tumour-inﬁltrating monocytes and B
cells or by an as yet poorly deﬁned direct effect on cells of the
immune system or haematopoietic cells in the bone marrow. More-
over, IL-6 is an acute phase cytokine, that can be produced by
hepatocytes during liver inﬂammation, an effect that cannot at
present be excluded as representing a direct hepatocyte reaction
to taxanes. As paclitaxel acts through the activation of NF-kB, it
is well known that the latter transcriptionally activates both IL-2
and IL-2Ra genes (Lee and Jeon, 2001).
In vitro effects of docetaxel on the human colon carcinoma cell
line HT-29 have been studied with respect to the expression of
different adhesion and surface marker molecules, the adhesion
and immunocytotoxicity of peripheral blood lymphocytes and the
secretion of IFN-g and TNF-a. Docetaxel increased the expression
of the adhesion molecules LFA-3, ICAM-1, CD44s+v6 isoforms,
CD15, CD13 and VLA-4/5/6 on the tumour cells. Unstimulated
and LAK cells demonstrated a better adherence to and cytotoxicity
against docetaxel-pretreated HT-29 cells than to untreated cells.
The authors concluded, that the increased lymphocyte mediated
cytotoxicity against docetaxel treated HT-29 colon carcinoma cells
might reﬂect an immunological process coupled with docetaxel-
induced upregulation of adhesion or costimulatory molecules, that
may contribute to the clinically known cytostatic effects of the drug
(Grunberg et al, 1998). Similarly, docetaxel or both taxanes might
have induced upregulation of breast cancer cell adhesion molecules
leading to enhanced NK and LAK cell-mediated cytotoxicity, that
has been measured in the peripheral blood.
A link between enhanced production and eventually release of
immuno-enhancing cytokines in the peripheral blood, particularly
IL-2, but also IFN-g, and GM-SCF, as detected in the present study
after taxane treatment, as well as IL-12 and IL-15 in other studies
after monoclonal antibody therapy (MoAb 17-1A) (Baxevanis et al,
submitted) and the observed enhancement of lymphocyte ability to
respond to autologous stimuli via proliferation (overall increase in
AMLR by almost 200–250%) or to efﬁciently exert their tumour-
icidal action via lysis of tumour targets can be envisaged.
Moreover, an important aspect of the present study was that base-
line pretreatment measurements of IL-2, IFN-g, and GM-CSF
serum levels, as well as NK and LAK cell cytotoxicity were
depressed in patients (either in the paclitaxel or docetaxel group)
compared to healthy normal blood donors, indicating impaired
immunity at the start of treatment, a ﬁnding that is consistent to
those regarding other tumour types investigated by our group in
the past, such as colon cancer, melanoma and renal–cell carcino-
ma. For instance, most patients with colon cancer had impaired
immunological parameter values after surgery, before the start of
treatment and these returned to normal or surpassed it after
responding to immunotherapeutic manoeuvres (Tsavaris et al,
1996; Baxevanis et al, 1997). In contrast, IL-6 serum levels were
increased in our breast cancer patients at baseline, compared to
normal controls and raised further signiﬁcantly after treatment
with both taxanes, a ﬁnding that might point to a direct effect
of taxanes on hepatocytes or enhancement of tumour-induced
Th2-directed inﬂammatory reaction. The latter is in accordance
to the known type I hypersensitivity effects of taxanes and it is well
established that allergic reactions are driven by a Th2-type immu-
nity leading to IL-4, IL-5, IL-6, and IL-10 cytokine production.
Another issue pertaining to the results of the present study is the
interaction between tumour response and changes in the examined
immunological parameters. As set out in the eligibilty for the
present study, evaluation was carried-out before treatment and
after six cycles of either taxane, thus making eligible patients
who were able to complete the whole treatment course. This means
that only patients with non-progressive disease during therapy were
evaluable for the aforementioned immune changes. Moreover,
there was no difference in the examined parameters, neither in
their pre-treatment or post-treatment values between responders
(those attaining CR and/or PR) and those achieving stable disease
(SD) (data not shown). Moreover, the ﬁndings of the present study
could in another means indicate that the signiﬁcant changes
observed might be ascribed to restoration of immune function after
successful tumour eradication or growth arrest, or alternatively an
apoptosis-mediated inﬂammatory reaction generated at tumour
sites.
A recent study reported by the University of Herakleion-Crete
group evaluated various lymphocyte subpopulations before and
after treatment with single-agent docetaxel, administered either
weekly or 3-weekly, in 46 chemotherapy-naı ¨ve patients with a vari-
ety of solid tumours (Kotsakis et al, 2000). Their ﬁndings were
consistent with a progressive decline in all T-lymphocyte subpopu-
lations, namely CD3+, CD4+, CD8+, and CD56+ T or activated
killer cells, but no or minimal effect on the CD20+ B-cell subpo-
pulation. Very importantly, docetaxel caused a profound but
reversible lymphopenia that was associated with an increased risk
of non-neutropenic (very likely) opportunistic infections (Kotsakis
et al, 2000). These ﬁndings might at ﬁrst sight seem to contradict
ours, however, the studies bear important differences in their
design and the parameters evaluated. For instance, in the Crete
study no serum cytokines or lymphocyte functional assays were
performed, other than measurement of various lymphocyte subpo-
pulations, whereas in our study we did not enumerate lymphocyte
subsets. In addition, the cohort of patients in the Crete study was
heterogenous with just 10 out of 46 patients with breast cancer and
the remaining with lung, endometrial, ovarian cancers, etc, imply-
ing that it cannot be ruled out that a signiﬁcant proportion might
have poorly controllable diseases that might result in immunosup-
pression in conjunction with docetaxel therapy.
In conclusion, the present study indicates that treatment of
advanced breast cancer patients with single-agent paclitaxel or
docetaxel leads to an increase in serum IFN-g, IL-2, IL-6, GM-
CSF cytokine levels and enhancement of PBMC NK and LAK cell
activity, while they both lead to a decrease of acute phase serum
cytokine levels of IL-1 and TNF-a. Moreover, the effects of doce-
taxel are in all the above parameters more pronounced than
those of paclitaxel. These ﬁndings urge for more light into the
molecular mechanisms operating at the tumour cell or immune cell
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to be examined in the context of clinical outcome after therapy in
large prospective randomised studies evaluating taxane-based
chemotherapy.
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